Myo-Inositol Trispyrophosphate (ITPP) Powder

Description

Introduction

ITPP, or myo-Inositol Trispyrophosphate, is a highly phosphorylated derivative of myo-inositol that has gained attention in research for its ability to modify oxygen release from hemoglobin. It is primarily studied in laboratory and animal models for its potential effects on metabolic efficiency and cardiovascular performance.

Key Characteristics

Molecularly modified to enhance oxygen unloading from red blood cells, ITPP is highly soluble and stable in aqueous environments and is often utilized in capsule, tablet, or powder form for experimental protocols.

Research Applications

Enhanced Endurance in Models

ITPP has been used in preclinical studies to investigate improvements in exercise capacity and endurance metrics in animal models.

Increased Stamina Potential

Studies suggest ITPP can support sustained physical activity by improving oxygen availability at the tissue level.

Accelerated Recovery Studies

Research explores its role in promoting faster recovery from metabolic stress or high-intensity exertion in controlled experimental settings.

Summary

ITPP serves as a valuable compound in research exploring oxygen transport, endurance enhancement, and recovery mechanisms. Its application in experimental studies contributes to a better understanding of metabolic and cardiovascular dynamics under controlled conditions.

Disclaimer

This content is presented exclusively for educational purposes and should not be construed as medical advice. THE MATERIALS REFERENCED HEREIN ARE EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH USE.

Any clinical research initiatives must be conducted under the guidance of the relevant Institutional Review Board (IRB). Similarly, preclinical research involving animals must comply with the directives of the Institutional Animal Care and Use Committee (IACUC), adhering to the standards delineated by the Animal Welfare Act (AWA).

Our informational content is meticulously designed for research-oriented insights and is not a substitute for individual analysis and verification from credible sources before any purchasing decisions are made.

Upon the finalization of your order and payment, you explicitly acknowledge and agree to adhere to our Terms and Conditions. Customer contentment stands as our paramount concern. Should you find any dissatisfaction with the product received, kindly contact us at 419-707-5450 or email our support team at support@bc9.co.

IMPORTANT NOTICE: All products showcased on our platform are EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH APPLICATIONS. They are expressly not intended for veterinary or human utilization.

References

Görgens, C. (2014). Screening and confirmation of myo‐inositol trispyrophosphate in human urine by ion chromatography coupled to high‐resolution mass spectrometry. Drug Testing and Analysis, 6(10), 1000–1006 [Read More].

Wong, A. S. Y., Ho, E. N. M., & Wan, T. S. M. (2012). Detection of myo‐inositol trispyrophosphate in equine urine and plasma by hydrophilic interaction chromatography‐tandem mass spectrometry. Drug Testing and Analysis, 4(5), 355–361.[Read More].

Görgens, C., Guddat, S., Schänzer, W., & Thevis, M. (2014). Screening and confirmation of myo-inositol trispyrophosphate (ITPP) in human urine by hydrophilic interaction liquid chromatography high resolution/high-accuracy mass spectrometry for doping control purposes. Drug Testing and Analysis, 6(11–12), 1102–1107.[Read More].